{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:15:55Z","timestamp":1707524155039},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,29]]},"DOI":"10.7759\/cureus.11231","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T10:47:38Z","timestamp":1603968458000},"source":"Crossref","is-referenced-by-count":0,"title":["Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib"],"prefix":"10.7759","author":[{"given":"Saro","family":"Sarkisian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander N","family":"Shoushtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21332","article-title":"Cancer Statistics, 2016","volume":"66","author":"Siegel RL","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. CA Cancer J Clin. 2016, 66:7-30.","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2010.03.019","article-title":"BRAF as a therapeutic target in melanoma","volume":"80","author":"Wellbrock C","year":"2010","unstructured":"Wellbrock C, Hurlstone A. BRAF as a therapeutic target in melanoma. Biochem Pharmacol. 2010, 80:561-567.","journal-title":"Biochem Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1005370","article-title":"Melanoma, an unlikely poster child for personalized cancer therapy","volume":"363","author":"Smalleys KS","year":"2010","unstructured":"Smalleys KS, Sondak VK. Melanoma, an unlikely poster child for personalized cancer therapy. NEJM. 2010, 363:876-878. 10.1056\/NEJMe1005370","journal-title":"NEJM"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long GV","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, et al.. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011, 29:1239-1240. 10.1200\/JCO.2010.32.4327","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","author":"The AACR Project GENIE Consortium","year":"2017","unstructured":"The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017, 7:818-883. 10.1158\/2159-8290.CD-17-0151","journal-title":"Cancer Discovery"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6161-8","article-title":"FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR","volume":"19","author":"Li L","year":"2019","unstructured":"Li L, Zhang S, Li H, et al.. FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR. BMC Cancer. 2019, 19:963. 10.1186\/s12885-019-6161-8","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1097\/00008390-199708000-00004","article-title":"Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma","volume":"7","author":"Ahmed NU","year":"1997","unstructured":"Ahmed NU, Ueda M, Ito A, et al.. Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Res. 1997, 7:299-305.","journal-title":"Melanoma Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.51","article-title":"FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer","volume":"2","author":"Theelen WS","year":"2016","unstructured":"Theelen WS, Mittempergher L, Willems SM, et al.. FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer. J Pathol Clin Res. 2016, 2:223-233. 10.1002\/cjp2.51","journal-title":"J Pathol Clin Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086470","article-title":"Fibroblast growth factor receptor 3 interacts with and activates TGF beta activated kinase 1 tyrosine phosphorylation and NFkappaB signaling in multiple myeloma and bladder cancer","volume":"9","author":"Salazar L","year":"2014","unstructured":"Salazar L, Kashiwada T, Krejci P, et al.. Fibroblast growth factor receptor 3 interacts with and activates TGF beta activated kinase 1 tyrosine phosphorylation and NFkappaB signaling in multiple myeloma and bladder cancer. PLoS One. 2014, 9:e86470. 10.1371\/journal.pone.0086470","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.595","article-title":"Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma","volume":"5","author":"Koole K","year":"2016","unstructured":"Koole K, van Kempen PM, Swartz JE, et al.. Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Med. 2016, 5:275-284. 10.1002\/cam4.595","journal-title":"Cancer Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson DC","year":"2007","unstructured":"Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007, 213:91-98. 10.1002\/path.2207","journal-title":"J Pathol"},{"key":"ref12","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. (2019). http.\/\/FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot Y","year":"2019","unstructured":"Loriot Y, Necchi A, Park S, et al.. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019, 381:338-348. 10.1056\/NEJMoa1817323","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/38747-fibroblast-growth-factor-receptor-3-amplified-metastatic-melanoma-treated-with-erdafitinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:19:17Z","timestamp":1707506357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/38747-fibroblast-growth-factor-receptor-3-amplified-metastatic-melanoma-treated-with-erdafitinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.11231","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,29]]}}}